Stockreport

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly ...

Wave Life Sciences Ltd. - Ordinary Shares  (WVE) 
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am Check Earnings Report
PDF Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, [Read more]